JP2016512203A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512203A5 JP2016512203A5 JP2015561914A JP2015561914A JP2016512203A5 JP 2016512203 A5 JP2016512203 A5 JP 2016512203A5 JP 2015561914 A JP2015561914 A JP 2015561914A JP 2015561914 A JP2015561914 A JP 2015561914A JP 2016512203 A5 JP2016512203 A5 JP 2016512203A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 63
- 150000003839 salts Chemical class 0.000 claims description 43
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 14
- -1 aralkenyl Chemical group 0.000 claims description 11
- BQEUECRVCKCNDI-UHFFFAOYSA-N 4-[4-(2-fluoro-5-methylphenyl)-4-hydroxypiperidine-1-carbonyl]-n-(1,3-thiazol-2-yl)benzenesulfonamide Chemical compound CC1=CC=C(F)C(C2(O)CCN(CC2)C(=O)C=2C=CC(=CC=2)S(=O)(=O)NC=2SC=CN=2)=C1 BQEUECRVCKCNDI-UHFFFAOYSA-N 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 claims description 8
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 claims description 8
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 8
- BFBYUBBUQICKBI-UHFFFAOYSA-N 4-[4-hydroxy-4-(4-methylphenyl)piperidine-1-carbonyl]-n-(1,3-thiazol-2-yl)benzenesulfonamide Chemical compound C1=CC(C)=CC=C1C1(O)CCN(C(=O)C=2C=CC(=CC=2)S(=O)(=O)NC=2SC=CN=2)CC1 BFBYUBBUQICKBI-UHFFFAOYSA-N 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 210000003743 erythrocyte Anatomy 0.000 claims description 5
- 208000007475 hemolytic anemia Diseases 0.000 claims description 5
- FKIRFDIHZTZLHM-UHFFFAOYSA-N 4-[4-(3-fluorophenyl)-4-hydroxypiperidine-1-carbonyl]-n-(1,3-thiazol-2-yl)benzenesulfonamide Chemical compound C1CC(O)(C=2C=C(F)C=CC=2)CCN1C(=O)C(C=C1)=CC=C1S(=O)(=O)NC1=NC=CS1 FKIRFDIHZTZLHM-UHFFFAOYSA-N 0.000 claims description 4
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 4
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000006413 ring segment Chemical group 0.000 claims description 4
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 claims description 2
- VKTRIIOQTOLRAS-UHFFFAOYSA-N 4-[4-(4-chlorophenyl)-4-hydroxypiperidine-1-carbonyl]-n-(1,3-thiazol-2-yl)benzenesulfonamide Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1C(=O)C(C=C1)=CC=C1S(=O)(=O)NC1=NC=CS1 VKTRIIOQTOLRAS-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- BAJLNYHQTYVIOS-UHFFFAOYSA-N methyl 1-[4-[(2-methylphenyl)sulfamoyl]benzoyl]-4-phenylpiperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)(C=2C=CC=CC=2)CCN1C(=O)C(C=C1)=CC=C1S(=O)(=O)NC1=CC=CC=C1C BAJLNYHQTYVIOS-UHFFFAOYSA-N 0.000 claims description 2
- WXRMODUITVDKEN-UHFFFAOYSA-N methyl 4-phenyl-1-[4-(phenylsulfamoyl)benzoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)(C=2C=CC=CC=2)CCN1C(=O)C(C=C1)=CC=C1S(=O)(=O)NC1=CC=CC=C1 WXRMODUITVDKEN-UHFFFAOYSA-N 0.000 claims description 2
- AUWWKKUWIICCOE-UHFFFAOYSA-N n-(4-fluorophenyl)-4-[4-hydroxy-4-(methoxymethyl)piperidine-1-carbonyl]benzenesulfonamide Chemical compound C1CC(COC)(O)CCN1C(=O)C1=CC=C(S(=O)(=O)NC=2C=CC(F)=CC=2)C=C1 AUWWKKUWIICCOE-UHFFFAOYSA-N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 208000005980 beta thalassemia Diseases 0.000 claims 4
- 208000022806 beta-thalassemia major Diseases 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 108700014121 Pyruvate Kinase Deficiency of Red Cells Proteins 0.000 claims 2
- 208000035623 congenital anemia Diseases 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- 208000030760 Anaemia of chronic disease Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- 208000004622 abetalipoproteinemia Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000022400 anemia due to chronic disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 208000009601 hereditary spherocytosis Diseases 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 9
- 101001091538 Homo sapiens Pyruvate kinase PKM Proteins 0.000 description 4
- 102100034911 Pyruvate kinase PKM Human genes 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- DWOBOHJJJHTHGQ-UHFFFAOYSA-N CC(C)CC(CC1)(CCN1C(c(cc1)ccc1NS(c1c2nc(N)[s]c2ccc1)(=O)=O)=O)O Chemical compound CC(C)CC(CC1)(CCN1C(c(cc1)ccc1NS(c1c2nc(N)[s]c2ccc1)(=O)=O)=O)O DWOBOHJJJHTHGQ-UHFFFAOYSA-N 0.000 description 1
- JTGUGSWLWPKCGF-UHFFFAOYSA-N CC(C)CC(CC1)(CCN1C(c(cc1)ccc1NS(c1c2nccnc2ccc1)(=O)=O)=O)O Chemical compound CC(C)CC(CC1)(CCN1C(c(cc1)ccc1NS(c1c2nccnc2ccc1)(=O)=O)=O)O JTGUGSWLWPKCGF-UHFFFAOYSA-N 0.000 description 1
- PNHFJXKSMARJSQ-UHFFFAOYSA-N CC(C)CC(CC1)(CCN1C(c(cc1)ccc1NS(c1cccc2c1ncnc2O)(=O)=O)=O)O Chemical compound CC(C)CC(CC1)(CCN1C(c(cc1)ccc1NS(c1cccc2c1ncnc2O)(=O)=O)=O)O PNHFJXKSMARJSQ-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/072688 WO2014139144A1 (en) | 2013-03-15 | 2013-03-15 | Therapeutic compounds and compositions |
| CNPCT/CN2013/072688 | 2013-03-15 | ||
| PCT/CN2014/000260 WO2014139325A1 (en) | 2013-03-15 | 2014-03-13 | Therapeutic compounds and compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017042775A Division JP2017105832A (ja) | 2013-03-15 | 2017-03-07 | 治療化合物および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512203A JP2016512203A (ja) | 2016-04-25 |
| JP2016512203A5 true JP2016512203A5 (enExample) | 2017-04-13 |
| JP6374413B2 JP6374413B2 (ja) | 2018-08-15 |
Family
ID=51535825
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561914A Expired - Fee Related JP6374413B2 (ja) | 2013-03-15 | 2014-03-13 | 治療化合物および組成物 |
| JP2017042775A Withdrawn JP2017105832A (ja) | 2013-03-15 | 2017-03-07 | 治療化合物および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017042775A Withdrawn JP2017105832A (ja) | 2013-03-15 | 2017-03-07 | 治療化合物および組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20160046579A1 (enExample) |
| EP (1) | EP2970189B1 (enExample) |
| JP (2) | JP6374413B2 (enExample) |
| CN (1) | CN105121425A (enExample) |
| AR (1) | AR095557A1 (enExample) |
| AU (1) | AU2014231564B2 (enExample) |
| BR (1) | BR112015023760A2 (enExample) |
| CA (1) | CA2903067A1 (enExample) |
| CL (1) | CL2015002767A1 (enExample) |
| CR (1) | CR20150571A (enExample) |
| ES (1) | ES2803548T3 (enExample) |
| HK (1) | HK1216175A1 (enExample) |
| IL (1) | IL241352A0 (enExample) |
| MX (1) | MX2015012882A (enExample) |
| NI (1) | NI201500140A (enExample) |
| PE (1) | PE20151793A1 (enExample) |
| PH (1) | PH12015502161A1 (enExample) |
| RU (1) | RU2015143908A (enExample) |
| SG (1) | SG11201507332SA (enExample) |
| TW (1) | TW201444797A (enExample) |
| WO (2) | WO2014139144A1 (enExample) |
| ZA (1) | ZA201506487B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014139144A1 (en) * | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| RS62017B1 (sr) | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| CN104817490B (zh) * | 2015-05-13 | 2017-10-13 | 北京大学 | 氨基二硫代甲酸酯类化合物及其制备方法与应用 |
| WO2017100599A1 (en) | 2015-12-09 | 2017-06-15 | Luc Therapeutics | Thienopyrimidinone nmda receptor modulators and uses thereof |
| ES2821010T3 (es) | 2015-12-09 | 2021-04-23 | Cadent Therapeutics Inc | Moduladores heteroaromáticos del receptor NMDA y usos de los mismos |
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| AU2017382339B2 (en) | 2016-12-22 | 2024-02-15 | Novartis Ag | NMDA receptor modulators and uses thereof |
| AR111295A1 (es) * | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| CN107298685A (zh) * | 2017-06-29 | 2017-10-27 | 上海合全药业股份有限公司 | 一种8‑(叔丁氧羰基)‑1‑氧杂‑8‑氮杂螺[4.5]癸烷‑2‑羧酸的合成方法 |
| EP3668513B1 (en) | 2017-08-15 | 2021-11-10 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in treating blood disorders |
| KR20200125758A (ko) | 2017-10-27 | 2020-11-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 피리딘 카보닐 유도체 및 trpc6 억제제로서 이의 치료학적 용도 |
| ES2987073T3 (es) | 2018-08-02 | 2024-11-13 | Dev Ct Biotechnology | Proceso regioselectivo de un solo paso para sintetizar 2-hidroxiquinoxalina |
| PT3830092T (pt) | 2018-08-03 | 2023-07-25 | Novartis Ag | Moduladores do recetor nmda heteroaromáticos e suas utilizações |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| ES3010713T3 (en) * | 2018-12-18 | 2025-04-04 | D Western Therapeutics Inst Inc | Isoquinoline sulfonyl chloride acid addition salts and method of manufacture thereof |
| WO2021029450A1 (ko) * | 2019-08-09 | 2021-02-18 | 한국화학연구원 | 신규한 피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 |
| MX2022003025A (es) | 2019-09-19 | 2022-04-07 | Forma Therapeutics Inc | Activacion de la piruvato cinasa r. |
| CA3188340A1 (en) | 2020-08-13 | 2022-02-17 | Boehringer Ingelheim International Gmbh | Treatment of cognitive impairement associated with schizophrenia |
| KR20230088761A (ko) | 2020-10-13 | 2023-06-20 | 베링거 인겔하임 인터내셔날 게엠베하 | 재가공하는 방법 |
| CN112773800B (zh) * | 2021-01-25 | 2021-10-15 | 南通大学 | 哌啶-1-二硫代甲酸-3-甲基-1，4-二氧-1，4-二氢萘-2-甲基酯的用途 |
| WO2022170200A1 (en) | 2021-02-08 | 2022-08-11 | Global Blood Therapeutics, Inc. | 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| CN117337292A (zh) | 2021-05-12 | 2024-01-02 | 勃林格殷格翰国际有限公司 | 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物 |
| BR112023020381A2 (pt) * | 2021-05-12 | 2023-11-21 | Boehringer Ingelheim Int | Derivados de piridina com substituintes cíclicos ligados por c como inibidores de cgas |
| TWI841134B (zh) | 2021-12-21 | 2024-05-01 | 大陸商賽諾哈勃藥業（成都）有限公司 | 含二氮雜亞基磺醯結構的化合物及其在醫藥上的用途 |
| CN115073422A (zh) * | 2022-07-28 | 2022-09-20 | 成都普瑞熙药业有限公司 | 一种制备4-(1-甲基-1h-吡唑-5-基)哌啶及其盐的方法 |
| ES2975743A1 (es) * | 2022-11-22 | 2024-07-12 | Moehs Iberica Sl | Metodo de preparacion de mitapivat, intermedios de sintesis de mitapivat y metodos de preparacion de los mismos |
| WO2024245143A1 (zh) | 2023-05-26 | 2024-12-05 | 赛诺哈勃药业（成都）有限公司 | 含二氮杂亚基磺酰结构化合物的药物组合物在治疗贫血相关疾病中的用途 |
| WO2025191185A1 (en) * | 2024-03-15 | 2025-09-18 | Domain Therapeutics | Azine-based compounds as par-2 inhibitors and therapeutic uses thereof |
| WO2025233901A1 (en) | 2024-05-09 | 2025-11-13 | Biohaven Therapeutics Ltd. | Activators of pyruvate kinase isoform m2 and methods for treating neurodegenerative disease |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE508815A (enExample) | 1949-07-23 | |||
| GB935538A (en) | 1959-04-06 | 1963-08-28 | Stop Motion Devices Corp | Stop-motion head for use on knitting machines |
| US4474599A (en) | 1982-07-14 | 1984-10-02 | The Dow Chemical Company | 1-(Pyridyl)-1H-1,2,3-triazole derivatives, and use as herbicidal agents |
| GB8325370D0 (en) | 1983-09-22 | 1983-10-26 | Fujisawa Pharmaceutical Co | Benzoxazoline and benzothiazoline derivatives |
| JPS61129129A (ja) | 1984-11-28 | 1986-06-17 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| FI855180L (fi) | 1985-01-18 | 1986-07-19 | Nissan Chemical Ind Ltd | Pyrazolsulfonamidderivat, foerfarande foer dess framstaellande och det innehaollande ograesgift. |
| EP0246749A3 (en) | 1986-05-17 | 1988-08-31 | AgrEvo UK Limited | Triazole herbicides |
| JPS6339875A (ja) | 1986-08-05 | 1988-02-20 | Nissin Food Prod Co Ltd | ピリミジン誘導体 |
| US4775762A (en) | 1987-05-11 | 1988-10-04 | The Dow Chemical Company | Novel (1H-1,2,3-triazol-1-yl)pyridines |
| DE3813885A1 (de) | 1988-04-20 | 1989-11-02 | Schering Ag | 1-chlorpyrimidinyl-1h-1,2,4-triazol-3-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung |
| DE3813886A1 (de) | 1988-04-20 | 1989-11-02 | Schering Ag | 1-triazinyl-1h-1,2,4-triazol-3- sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung |
| US5220028A (en) | 1988-10-27 | 1993-06-15 | Nissan Chemical Industries, Ltd. | Halogeno-4-methylpyrazoles |
| MY106533A (en) | 1990-02-20 | 1995-06-30 | Sumitomo Chemical Co | A 4-tert.-butyl imidazole derivative and its production and use. |
| CA2036148A1 (en) | 1990-06-29 | 1991-12-30 | Hiroki Tomioka | A 1-phenylimidazole derivative and its production and use |
| ES2130166T3 (es) | 1990-12-31 | 1999-07-01 | Monsanto Co | Reduccion de la interaccion de pesticidas en cosechas. |
| US5252590A (en) | 1991-06-28 | 1993-10-12 | Sumitomo Chemical Company, Limited | 1-pyridylimidazole derivative |
| JPH0625177A (ja) | 1992-07-09 | 1994-02-01 | Nissan Chem Ind Ltd | ピラゾール誘導体及び除草剤 |
| JP3719612B2 (ja) | 1993-06-14 | 2005-11-24 | 塩野義製薬株式会社 | ヘテロ環を含有する尿素誘導体 |
| DE19541146A1 (de) | 1995-10-25 | 1997-04-30 | Schering Ag | Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren |
| FR2744449B1 (fr) | 1996-02-02 | 1998-04-24 | Pf Medicament | Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments |
| BR9815453A (pt) | 1997-03-11 | 2001-10-23 | Du Pont | Composto, composição herbicida e método para controle do crescimento de vegetação indesejada |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| DE19743435A1 (de) | 1997-10-01 | 1999-04-08 | Merck Patent Gmbh | Benzamidinderivate |
| US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
| JP2002523451A (ja) | 1998-09-01 | 2002-07-30 | ブリストル−マイヤーズ スクイブ カンパニー | カリウムチャネル抑制剤および方法 |
| CZ2001959A3 (cs) | 1998-09-18 | 2001-12-12 | Basf Aktiengesellschaft | 4-Aminopyrrolopyrimidiny jako inhibitory kinasy |
| US6492408B1 (en) | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| CZ2002773A3 (cs) | 1999-09-04 | 2002-06-12 | Astrazeneca Ab | Substituované deriváty N-fenyl-2-hydroxy-2-methyl-3,3,3-trifluorpropanamidu, které zvyąují aktivitu pyruvátdehydrogenázy |
| JP2002193710A (ja) | 2000-12-25 | 2002-07-10 | Kumiai Chem Ind Co Ltd | ピリミジン又はトリアジン誘導体及び農園芸用殺菌剤 |
| EP1387679A4 (en) | 2001-05-07 | 2004-08-11 | Smithkline Beecham Corp | SULPHONAMIDES |
| DE60226875D1 (de) | 2001-08-15 | 2008-07-10 | Du Pont | Orthosubstituierte arylamide zur bekämpfung von wirbellosen schädlingen |
| JP2003081937A (ja) | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
| WO2003037252A2 (en) | 2001-10-30 | 2003-05-08 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP1472248A1 (en) | 2002-01-17 | 2004-11-03 | Eli Lilly And Company | Modulators of acetylcholine receptors |
| ES2306859T3 (es) | 2002-03-13 | 2008-11-16 | Janssen Pharmaceutica Nv | Derivados de sulfonil como nuevos inhibidores de histona deacetilasa. |
| AU2003234464B2 (en) | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| GB0215775D0 (en) | 2002-07-06 | 2002-08-14 | Astex Technology Ltd | Pharmaceutical compounds |
| CA2494962C (en) | 2002-08-09 | 2011-06-14 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| KR20050059294A (ko) | 2002-10-24 | 2005-06-17 | 스테릭스 리미티드 | 11-베타-하이드록시 스테로이드 데하이드로게나제 형태 1및 형태 2의 억제제 |
| CN1744899A (zh) * | 2002-12-13 | 2006-03-08 | 史密丝克莱恩比彻姆公司 | 作为ccr5拮抗剂的哌啶衍生物 |
| DE602004027171D1 (de) * | 2003-04-11 | 2010-06-24 | High Point Pharmaceuticals Llc | Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase |
| EP1635800A2 (en) | 2003-06-10 | 2006-03-22 | Kalypsys, Inc. | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease |
| US6818631B1 (en) | 2003-08-15 | 2004-11-16 | Nippon Soda Co. Ltd. | Fungicidal pyrimidine derivatives |
| US20080051414A1 (en) | 2003-10-14 | 2008-02-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
| JP2008514590A (ja) | 2004-09-24 | 2008-05-08 | アストラゼネカ・アクチエボラーグ | ベンゾイミダゾール誘導体、それを含む組成物、その製造方法及びその使用 |
| WO2006038594A1 (ja) * | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| WO2006043950A1 (en) | 2004-10-20 | 2006-04-27 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| EP1807417A2 (en) | 2004-11-04 | 2007-07-18 | Neurogen Corporation | Pyrazolylmethyl heteroaryl derivatives |
| SE0402762D0 (sv) | 2004-11-11 | 2004-11-11 | Astrazeneca Ab | Indazole sulphonamide derivatives |
| WO2006117762A2 (en) | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Antimicrobial agents |
| EP1910321A4 (en) | 2005-07-05 | 2010-09-01 | Astrazeneca Ab | NEW COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, INTERMEDIATE PRODUCTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6-MEDIATED ILLNESSES SUCH AS ALZHEIMER'S DISEASE, COGNITIVE ILLUSTRATIONS, SCHOISOPHRENIC ASSOCIATED COGNITIVE DISORDERS, OBESITAS AND PARKINSON DISEASE |
| US20080214495A1 (en) | 2005-07-08 | 2008-09-04 | Astrazeneca Ab | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa |
| TW200730485A (en) | 2005-07-29 | 2007-08-16 | Kalypsys Inc | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| US7345178B2 (en) | 2005-08-04 | 2008-03-18 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| JP2007238458A (ja) | 2006-03-06 | 2007-09-20 | D Western Therapeutics Institute Inc | 新規なイソキノリン誘導体及びこれを含有する医薬 |
| CN101448803A (zh) | 2006-03-17 | 2009-06-03 | 阿斯利康(瑞典)有限公司 | 用作5-ht6调节剂的四氢萘 |
| AU2007231594A1 (en) | 2006-03-23 | 2007-10-04 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
| US8008481B2 (en) | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| AU2007281911B2 (en) | 2006-08-04 | 2014-02-06 | Beth Israel Deaconess Medical Center | Inhibitors of pyruvate kinase and methods of treating disease |
| US20090247499A1 (en) | 2006-08-21 | 2009-10-01 | Fletcher Joan M | Sulfonylated piperazines as cannabinoid-1 receptor modulators |
| US7994094B2 (en) | 2006-09-01 | 2011-08-09 | Otsuka Agritechno Co., Ltd. | N-pyridylpiperidine compound, method for producing the same, and pest control agent |
| EP2527345B1 (en) | 2006-10-16 | 2015-12-16 | Thesan Pharmaceuticals, Inc. | Therapeutic pyrazolyl thienopyridines |
| HUP0600810A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| CL2008000835A1 (es) * | 2007-03-23 | 2008-10-03 | Icagen Inc Pfizer Ltd | Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm |
| PA8790401A1 (es) | 2007-07-18 | 2009-03-31 | Janssen Pharmaceutica Nv | Sulfonamidas como moduladores de trpm8 |
| US20110224252A1 (en) | 2007-10-26 | 2011-09-15 | Syngenta Crop Protection, Inc. | Novel imidazole derivatives |
| EP2053045A1 (en) | 2007-10-26 | 2009-04-29 | Syngenta Participations AG | Novel imidazole derivatives |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| BRPI0917575A2 (pt) * | 2008-08-05 | 2019-09-24 | Targegen Inc | métodos de tratamento de talassemia |
| JP2012500783A (ja) * | 2008-08-22 | 2012-01-12 | エヴォテック・アクチエンゲゼルシャフト | 新しいブラジキニンｂ１拮抗薬 |
| GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| ES2620634T3 (es) | 2008-10-09 | 2017-06-29 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Activadores de piruvato quinasa humana |
| JP5756457B2 (ja) | 2009-04-06 | 2015-07-29 | アジオス ファーマシューティカルズ， インコーポレイテッド | ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法 |
| AU2010239188B2 (en) | 2009-04-22 | 2016-03-31 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| PL2427441T3 (pl) | 2009-05-04 | 2017-06-30 | Agios Pharmaceuticals, Inc. | Aktywatory PKM2 do stosowania w leczeniu raka |
| WO2010130638A1 (en) * | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
| PE20120693A1 (es) * | 2009-06-29 | 2012-07-04 | Agios Pharmaceuticals Inc | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) |
| US20130035304A1 (en) | 2010-01-29 | 2013-02-07 | Walensky Loren D | Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders |
| BR112012021806A2 (pt) | 2010-03-01 | 2015-09-08 | Myrexis Inc | compostos e seus usos terapêusticos. |
| US20130109672A1 (en) | 2010-04-29 | 2013-05-02 | The United States Of America,As Represented By The Secretary, Department Of Health And Human Service | Activators of human pyruvate kinase |
| DE102010048800A1 (de) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | Chinoxalinderivate |
| FR2967674B1 (fr) | 2010-11-23 | 2012-12-14 | Pf Medicament | Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine |
| US9221792B2 (en) * | 2010-12-17 | 2015-12-29 | Agios Pharmaceuticals, Inc | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators |
| EP2704720B1 (en) * | 2011-05-03 | 2019-08-07 | Agios Pharmaceuticals, Inc. | Pyruvate kinase r activators for use in therapy |
| CN102805860A (zh) * | 2011-05-30 | 2012-12-05 | 复旦大学 | 丙酮酸激酶2乙酰化抑制剂及其用途 |
| WO2014139144A1 (en) * | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
-
2013
- 2013-03-15 WO PCT/CN2013/072688 patent/WO2014139144A1/en not_active Ceased
-
2014
- 2014-03-13 AU AU2014231564A patent/AU2014231564B2/en not_active Ceased
- 2014-03-13 EP EP14765650.8A patent/EP2970189B1/en active Active
- 2014-03-13 CA CA2903067A patent/CA2903067A1/en not_active Abandoned
- 2014-03-13 US US14/776,635 patent/US20160046579A1/en not_active Abandoned
- 2014-03-13 WO PCT/CN2014/000260 patent/WO2014139325A1/en not_active Ceased
- 2014-03-13 ES ES14765650T patent/ES2803548T3/es active Active
- 2014-03-13 JP JP2015561914A patent/JP6374413B2/ja not_active Expired - Fee Related
- 2014-03-13 RU RU2015143908A patent/RU2015143908A/ru not_active Application Discontinuation
- 2014-03-13 CN CN201480021459.8A patent/CN105121425A/zh active Pending
- 2014-03-13 MX MX2015012882A patent/MX2015012882A/es unknown
- 2014-03-13 BR BR112015023760A patent/BR112015023760A2/pt not_active IP Right Cessation
- 2014-03-13 SG SG11201507332SA patent/SG11201507332SA/en unknown
- 2014-03-13 HK HK16104168.0A patent/HK1216175A1/zh unknown
- 2014-03-13 PE PE2015002010A patent/PE20151793A1/es not_active Application Discontinuation
- 2014-03-14 TW TW103109338A patent/TW201444797A/zh unknown
- 2014-03-14 US US14/210,583 patent/US9108921B2/en active Active
- 2014-03-17 AR ARP140101179A patent/AR095557A1/es unknown
-
2015
- 2015-07-31 US US14/814,862 patent/US9365545B2/en active Active
- 2015-09-03 ZA ZA2015/06487A patent/ZA201506487B/en unknown
- 2015-09-09 IL IL241352A patent/IL241352A0/en unknown
- 2015-09-15 PH PH12015502161A patent/PH12015502161A1/en unknown
- 2015-09-15 CL CL2015002767A patent/CL2015002767A1/es unknown
- 2015-09-16 NI NI201500140A patent/NI201500140A/es unknown
- 2015-10-15 CR CR20150571A patent/CR20150571A/es unknown
-
2017
- 2017-03-07 JP JP2017042775A patent/JP2017105832A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015143908A (ru) | Терапевтические соединения и композиции | |
| JP2016501189A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| RU2497822C2 (ru) | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний | |
| RU2451674C2 (ru) | Пиридинкарбоксамиды в качестве ингибиторов 11-бета-hsd1 | |
| JP2019507179A5 (enExample) | ||
| JP2011503103A5 (enExample) | ||
| JP2008110984A5 (enExample) | ||
| JP2017502940A5 (enExample) | ||
| JP2010508338A5 (enExample) | ||
| RU2012158142A (ru) | Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации | |
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| JP2017509694A5 (enExample) | ||
| JP2016512825A5 (enExample) | ||
| JP2019537603A5 (enExample) | ||
| KR960014125A (ko) | 헤테로사이클 화합물, 이들의 제조방법 및 용도 | |
| JP2015509535A5 (enExample) | ||
| RU2017145930A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
| IL273000B2 (en) | Compounds that inhibit lysophosphatidic acid receptor 1 (lpar1) | |
| JP2015524472A5 (enExample) | ||
| JP2006501201A5 (enExample) | ||
| JP2004512328A5 (enExample) | ||
| RU2011144763A (ru) | 6-(3-азабицикло[3.1.0]гекс-3-ил)-2-фенилпиримидины | |
| JP2016503797A5 (enExample) | ||
| RU2015123499A (ru) | Соединения замещенной триазолбороновой кислоты |